Sagramostim is named as an intervention in 3 current clinical trials in our Norway, Canada, Australia, Mexico and Israel registers. 1 is recruiting patients now. All registered phases are Phase 2. The sponsor with the most trials is Vestre Viken Hospital Trust (1). The most-studied condition is Oncology.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
NCT05344209 · ClinicalTrials.gov ↗ · Oncology, NSCLC Stage IV, NSCLC, Stage III
|
Phase 2 | Recruiting | Vestre Viken Hospital Trust | Norway |
|
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
NCT01134614 · ClinicalTrials.gov ↗ · Advanced Melanoma, Metastatic Melanoma, Recurrent Melanoma
|
Phase 2 | Active, closed | National Cancer Institute (NCI) | Mexico, Israel |
|
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)
NCT04385277 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Nodular, Neuroblastoma
|
Phase 2 | Active, closed | Children's Oncology Group | Canada, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Vestre Viken Hospital Trust | 1 |
| Children's Oncology Group | 1 |
| National Cancer Institute (NCI) | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Norway | 1 | 1 |
| Clinical trials in Canada | 1 | 0 |
| Clinical trials in Australia | 1 | 0 |
| Clinical trials in Mexico | 1 | 0 |
| Clinical trials in Israel | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our Norway, Canada, Australia, Mexico and Israel registers name Sagramostim as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 3 trials is recruiting: 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Vestre Viken Hospital Trust (1), Children's Oncology Group (1) and National Cancer Institute (NCI) (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Sagramostim works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sagramostim works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sagramostim (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.